Koshinski Asset Management Inc. Has $331,000 Holdings in Intuitive Surgical, Inc. $ISRG

Koshinski Asset Management Inc. lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 93.4% in the 4th quarter, Holdings Channel reports. The fund owned 584 shares of the medical equipment provider’s stock after selling 8,278 shares during the period. Koshinski Asset Management Inc.’s holdings in Intuitive Surgical were worth $331,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Intuitive Surgical by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock worth $15,026,776,000 after buying an additional 263,828 shares during the period. Capital World Investors lifted its stake in Intuitive Surgical by 1.5% in the 3rd quarter. Capital World Investors now owns 7,728,492 shares of the medical equipment provider’s stock worth $3,456,223,000 after acquiring an additional 116,034 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Intuitive Surgical by 1.1% in the 3rd quarter. Fisher Asset Management LLC now owns 3,889,439 shares of the medical equipment provider’s stock worth $1,739,475,000 after acquiring an additional 40,702 shares in the last quarter. Amundi boosted its position in Intuitive Surgical by 29.7% during the 3rd quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock worth $1,451,362,000 after acquiring an additional 739,444 shares during the period. Finally, Jennison Associates LLC boosted its position in Intuitive Surgical by 11.1% during the 4th quarter. Jennison Associates LLC now owns 3,209,137 shares of the medical equipment provider’s stock worth $1,817,527,000 after acquiring an additional 321,759 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $450.06 on Monday. The firm has a market cap of $159.39 billion, a PE ratio of 54.55, a PEG ratio of 3.59 and a beta of 1.51. The firm’s 50 day moving average price is $472.19 and its 200 day moving average price is $517.39. Intuitive Surgical, Inc. has a twelve month low of $427.84 and a twelve month high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 EPS for the quarter, topping the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a net margin of 28.15% and a return on equity of 15.98%. The company had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.62 billion. During the same period in the previous year, the firm posted $1.81 earnings per share. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 8.57 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ISRG shares. Truist Financial reduced their price target on shares of Intuitive Surgical from $650.00 to $580.00 and set a “buy” rating for the company in a research report on Wednesday, April 15th. Raymond James Financial cut their target price on shares of Intuitive Surgical from $615.00 to $577.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Sanford C. Bernstein lifted their target price on shares of Intuitive Surgical from $740.00 to $750.00 and gave the company an “outperform” rating in a research note on Friday, January 23rd. Barclays set a $651.00 price target on shares of Intuitive Surgical and gave the company an “overweight” rating in a report on Thursday, April 23rd. Finally, JPMorgan Chase & Co. dropped their price target on shares of Intuitive Surgical from $625.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 22nd. Eighteen equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $581.91.

Insiders Place Their Bets

In related news, EVP Myriam Curet sold 105 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $493.95, for a total value of $51,864.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Amy L. Ladd sold 119 shares of the stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $463.50, for a total transaction of $55,156.50. Following the transaction, the director directly owned 120 shares in the company, valued at $55,620. The trade was a 49.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,906 shares of company stock worth $2,907,726 in the last 90 days. 0.60% of the stock is owned by corporate insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.